Routine antenatal anti-D prophylaxis for women who are rhesus D negative
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta156
This guidance replaces 'The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy' (NICE technology appraisal guidance 41) issued in May 2002.
For details, see 'About this guidance'.
1.1 Routine antenatal anti-D prophylaxis (RAADP) is recommended as a treatment option for all pregnant women who are rhesus D (RhD) negative and who are not known to be sensitised to the RhD antigen.
1.2 When a decision has been made to give RAADP, the preparation with the lowest associated cost should be used. This cost should take into account the lowest acquisition cost available locally and costs associated with administration.